- Home
- LIVN
LIVN
LivaNova PLC
as 01-23-2025 4:00pm EST
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world.
| Founded: | 1987 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 2.8B | IPO Year: | 1993 |
| Target Price: | $67.14 | AVG Volume (30 days): | 458.1K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.43 | EPS Growth: | 759.09 |
| 52 Week Low/High: | $43.15 - $64.48 | Next Earning Date: | 02-25-2025 |
| Revenue: | $1,241,739,000 | Revenue Growth: | 11.04% |
| Revenue Growth (this year): | 10.1% | Revenue Growth (next year): | 5.43% |
Stock Insider Trading Activity of LivaNova PLC (LIVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bianchi Francesco | LIVN | Director | Dec 11 '24 | Sell | $50.99 | 1,250 | $63,737.50 | 7,522 |
Latest LivaNova PLC News
LIVN Breaking Stock News: Dive into LIVN Ticker-Specific Updates for Smart Investing
Argus Research
2 days ago
LIVN: Raising target price to $52.00
Business Wire
3 days ago
LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results
Argus Research
9 days ago
LIVN: Raising target price to $50.00
Morningstar Research
10 days ago
Analyst Report: LivaNova PLC
Business Wire
18 days ago
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
Zacks
25 days ago
5 Beaten-Down MedTech Stocks Set to Rebound in 2025
Argus Research
a month ago
LIVN: Lowering target price to $49.00
Business Wire
a month ago
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression
Compare LIVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LIVN LivaNova PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.